naa a22 4500 510764185 CHVBK 20180411083150.0 cr unu---uuuuu 180411e20130801xx s 000 0 eng 10.1007/s12094-012-0989-6 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0989-6 Cisplatin plus oral vinorelbine as first-line treatment for advanced non-small-cell lung cancer: a prospective study confirming that the day-8 hemogram is unnecessary [Elektronische Daten] [M. Provencio, A. Sánchez, A. Artal, J. Sánchez Torres, J. de Castro, M. Dómine, N. Viñolas, A. Sánchez, F. Pérez] Introduction: Cisplatin plus oral vinorelbine, one of the standard treatments for metastatic non-small-cell lung cancer (NSCLC), is associated with a high rate of neutropenia, and a hemogram is performed on day 8. We analyzed the oncologists' opinions and the result of the hemogram on day 8 to address the question of whether this hemogram could be avoided. Materials and methods: Fifty-eight chemotherapy-naive, advanced NSCLC patients were included. Each received intravenous doses of 75mg/m2 cisplatin on day 1 plus oral vinorelbine [60mg/m2 in the first cycle (80mg/m2 in subsequent cycles) on days 1 and 8], every 3weeks, for a maximum of six cycles. Results: Out of 257 cycles analyzed, oral vinorelbine was administered on day 8 in 214 (83.2%) and the dose was canceled in 6 cycles (2.3%) due to hematological toxicity. On analyzing the patients to whom chemotherapy had been administered on day 8, based on medical opinion without the doctor knowing the hemogram result, we found that the cycle had been administered with a hemogram showing fewer than 1,500×106 neutrophils in only 3 of the 185 evaluable cycles [event rate of 1.6%, with confidence interval 95%=(0.34-4.67%)]. Conclusion: The hemogram on day 8 can be avoided and oral vinorelbine administered in relative safety in patients with good performance status, when confirmed by the clinician's perception, thereby making this regimen more comfortable for the patient. This is the first prospective study to examine this issue. Federación de Sociedades Españolas de Oncología (FESEO), 2013 Non-small-cell lung cancer nationallicence Vinorelbine nationallicence Cisplatin nationallicence Neutropenia nationallicence Hemogram nationallicence Hematological toxicity nationallicence Provencio M. Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Calle Manuel de Falla 1, 28222, Madrid, Spain aut Sánchez A. Department of Medical Oncology, Hospital de Castellon, Castellon, Spain aut Artal A. Department of Medical Oncology, Hospital Miguel Servet, Zaragoza, Spain aut Sánchez Torres J. Department of Medical Oncology, Hospital MD Anderson, Madrid, Spain aut de Castro J. Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain aut Dómine M. Department of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain aut Viñolas N. Department of Medical Oncology, Hospital Clinic, Barcelona, Spain aut Sánchez A. Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Calle Manuel de Falla 1, 28222, Madrid, Spain aut Pérez F. Clinical Research Unit, Catalan Institute of Oncology, IDIBELL, Bellvitge, Catalonia, Spain aut Clinical and Translational Oncology Springer Milan 15/8(2013-08-01), 659-664 1699-048X 15:8<659 2013 15 12094 https://doi.org/10.1007/s12094-012-0989-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0989-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Provencio M. Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Calle Manuel de Falla 1, 28222, Madrid, Spain aut NATIONALLICENCE 700 1- Sánchez A. Department of Medical Oncology, Hospital de Castellon, Castellon, Spain aut NATIONALLICENCE 700 1- Artal A. Department of Medical Oncology, Hospital Miguel Servet, Zaragoza, Spain aut NATIONALLICENCE 700 1- Sánchez Torres J. Department of Medical Oncology, Hospital MD Anderson, Madrid, Spain aut NATIONALLICENCE 700 1- de Castro J. Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain aut NATIONALLICENCE 700 1- Dómine M. Department of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain aut NATIONALLICENCE 700 1- Viñolas N. Department of Medical Oncology, Hospital Clinic, Barcelona, Spain aut NATIONALLICENCE 700 1- Sánchez A. Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Calle Manuel de Falla 1, 28222, Madrid, Spain aut NATIONALLICENCE 700 1- Pérez F. Clinical Research Unit, Catalan Institute of Oncology, IDIBELL, Bellvitge, Catalonia, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/8(2013-08-01), 659-664 1699-048X 15:8<659 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer